Today, a Director at Epizyme (EPZM), David Mott, sold shares of EPZM for $651.7K.
See today’s analyst top recommended stocks >>
Based on Epizyme’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $7.89 million and GAAP net loss of $29.34 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $34.07 million. Currently, Epizyme has an average volume of 3.47M.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $22.67, reflecting a 80.6% upside.
The insider sentiment on Epizyme has been negative according to 22 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
David Mott’s trades have generated a -1.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
